Study #2022-0806
A phase 1b study of oral AS-1763 in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma or non hodgkin lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Docirbrutinib
Description
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
Study phase:
Phase I
Physician name:
Nitin Jain
Department:
Leukemia
For general questions about clinical trials:
1-844-285-5619
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.